Listen to the article
A U.S. appeals court has revived a significant whistleblower lawsuit accusing four major pharmaceutical companies of defrauding federal and state governments through overcharges in a program designed to help vulnerable patients access medications.
In a unanimous 3-0 decision, the 9th U.S. Circuit Court of Appeals in Pasadena, California ruled that AbbVie, AstraZeneca, Novartis, and Sanofi must defend against claims they violated the federal False Claims Act through their handling of the Section 340B Drug Pricing Program.
The lawsuit, brought by Adventist Health System/West, a California-based nonprofit healthcare provider that operates more than 440 hospitals and clinics, alleges that the pharmaceutical giants overcharged for medications intended for low-income and uninsured patients, resulting in inflated reimbursements from Medicare and Medicaid programs.
The Section 340B Drug Pricing Program, established by Congress in 1992, allows eligible healthcare providers to purchase drugs at discounted prices. Under the program’s “penny pricing” provision, medications should cost no more than $0.01 when statutory ceiling prices fall below zero.
According to Adventist, the alleged overcharges persisted for years until 2019, when the U.S. Department of Health and Human Services implemented a policy to impose substantial civil penalties for violations of the Section 340B pricing requirements. This regulatory change appears to have curtailed the alleged improper pricing practices.
Circuit Judge Roopali Desai, writing for the court, clarified an important legal distinction in the ruling. While Section 340B does not provide healthcare providers with a direct right to sue pharmaceutical companies for overcharges, they can pursue action under the False Claims Act to recover damages for alleged fraud that causes “financial loss” to the government.
“It does not matter” that Adventist cannot sue on its own behalf, Judge Desai wrote, because the claims in question “belong to the government.” This legal reasoning formed the basis for reviving the lawsuit, which had previously been dismissed by U.S. District Judge Dale Fischer in Los Angeles in March 2024.
The case now returns to the district court for further proceedings. Representatives from all four pharmaceutical companies—AbbVie, AstraZeneca, Novartis, and Sanofi—and their legal teams declined to comment on the ruling. Attorneys representing Adventist did not immediately respond to requests for comment.
This case highlights ongoing tensions between pharmaceutical manufacturers and healthcare providers regarding drug pricing transparency and compliance with federal programs. The 340B program has been a subject of considerable debate in recent years, with advocates arguing it provides critical support for safety-net providers serving vulnerable populations, while critics have questioned aspects of the program’s implementation and oversight.
The False Claims Act, under which this case proceeds, is a powerful tool that allows whistleblowers to sue on behalf of the government and share in any financial recoveries. These “qui tam” provisions create incentives for insiders with knowledge of fraud against government programs to come forward.
If successful, the lawsuit could potentially recover hundreds of millions of dollars in alleged overcharges, according to the plaintiff’s claims. Such an outcome would represent a significant victory for government healthcare programs and taxpayers.
The pharmaceutical industry, already under scrutiny for pricing practices, faces mounting pressure from various regulatory and legal challenges aimed at controlling healthcare costs. This case adds to those pressures while highlighting the complex interplay between government programs, healthcare providers, and drug manufacturers in the American healthcare system.
The court’s decision reinforces the government’s ability to pursue claims of fraud in healthcare programs through whistleblower actions, even when the immediate harm is felt by intermediary organizations like hospitals rather than directly by government agencies.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
21 Comments
Pharmaceutical pricing and transparency have long been contentious issues. This lawsuit highlights the need for stronger oversight and accountability to protect patient access, especially for essential medicines.
Indeed, the allegations of systematic overcharging are quite troubling. Robust enforcement of 340B rules is essential to uphold the program’s purpose of supporting safety-net providers and their patients.
The allegations of overcharging in the 340B program are very troubling. Patients who rely on this program should not have to worry about being exploited by pharmaceutical companies.
The 340B program was intended to help healthcare providers serve low-income and uninsured populations. If these allegations are true, it’s a betrayal of that core mission and the public trust.
I agree. Pharmaceutical companies have a responsibility to honor the intent and letter of the 340B law. Overcharging vulnerable patients is unacceptable and must be addressed.
The 340B program is an important safety net for vulnerable patients, so any evidence of systematic overcharging is very troubling. I hope this case leads to meaningful reforms and stronger protections.
This lawsuit raises important questions about the integrity of the 340B program and the pricing practices of major pharmaceutical companies. It’s crucial that these issues are thoroughly investigated and addressed.
Absolutely. The 340B program is too important to be undermined by corporate greed. Protecting patient access should be the top priority here.
This case highlights the need for greater transparency and accountability in the pharmaceutical industry, particularly when it comes to programs designed to help low-income and underserved populations.
I agree. Stricter oversight and tighter regulations around 340B pricing could go a long way in preventing these kinds of abuses and ensuring the program fulfills its intended purpose.
This lawsuit highlights the need for stronger oversight and accountability in the pharmaceutical industry, particularly when it comes to programs designed to help underserved communities access needed medications.
This lawsuit highlights the complex and often opaque nature of pharmaceutical pricing. Greater oversight and tighter regulations may be needed to prevent abuse of programs like 340B.
You make a good point. Simplifying and clarifying the rules around 340B pricing could help reduce the potential for exploitation by drug companies.
This is an important case that could have major implications for the 340B drug pricing program and access to affordable medications for low-income patients. I’m curious to see how the courts rule and what the broader impact will be.
You’re right, the 340B program is critical for ensuring vulnerable patients can access vital drugs. Any overcharging by pharmaceutical companies would be a serious abuse of the system.
The 340B program is a vital lifeline for many patients who would otherwise struggle to afford essential drugs. Any abuse of the system by pharmaceutical companies is deeply concerning and must be thoroughly investigated.
Agreed. Protecting the integrity of the 340B program should be a top priority to ensure continued access to affordable medications for low-income and uninsured individuals.
The 340B program is a critical lifeline for many vulnerable patients, so any evidence of overcharging or exploitation is deeply concerning. I’m glad to see the courts taking this case seriously.
It’s encouraging to see the courts taking these allegations seriously and allowing the case to move forward. Transparency and accountability are critical when it comes to drug pricing and patient access.
This is a concerning development that deserves close scrutiny. Pharmaceutical pricing and patient access are critical public health issues, and any abuse of the 340B system must be addressed.
Absolutely. The integrity of the 340B program is essential for ensuring equitable access to essential medications. This lawsuit could have far-reaching implications.